Hostname: page-component-7b7567c8c-w7t8q Total loading time: 0 Render date: 2026-11-18T08:27:13.495Z Has data issue: false hasContentIssue false

Levees for a hundred-year flood: impact of a syndrome-based antimicrobial stewardship intervention for coronavirus disease 2019 on antimicrobial use and resistance

Published online by Cambridge University Press:  18 September 2024

Alfredo J. Mena Lora*
Affiliation:
University of Illinois at Chicago, Chicago, IL, USASaint Anthony Hospital, Chicago, IL, USA
Rodrigo Burgos
Affiliation:
University of Illinois at Chicago, Chicago, IL, USA
Dylan Huber
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Lawrence Sanchez
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Mirza Ali
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Candice Krill
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Eden Takhsh
Affiliation:
Saint Anthony Hospital, Chicago, IL, USA
Susan C. Bleasdale
Affiliation:
University of Illinois at Chicago, Chicago, IL, USA
*
Corresponding author: Alfredo J. Mena Lora; Email: amenalor@uic.edu

Abstract

Coronavirus disease 2019 can be indistinguishable from lower respiratory tract infections (LRTIs) caused by other viral and bacterial agents. This likely contributed to antimicrobial use (AU) and antimicrobial resistance (AMR) during the pandemic. Our antimicrobial stewardship program targeted the selection and duration of therapy for LRTIs and led to a reduction in AU and AMR.

Information

Type
Concise Communication
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Figure 1.Monthly DOT per 1,000 patient days for ceftriaxone, cefepime, piperacillin, and meropenem during the study period.

Figure 1

Figure 2.Incidence rate per 1,000 patient days for extended-spectrum beta-lactamase (ESBL)-producing organisms and carbapenem-resistant Enterobacterales (CRE).

Supplementary material: File

Mena Lora et al. supplementary material

Mena Lora et al. supplementary material
Download Mena Lora et al. supplementary material(File)
File 269.2 KB